ORY-1001
ORY-1001 is a potent and selective inhibitor of LSD1 (IC₅₀ < 20 nM). It targets acute myeloid leukemia (AML) stem cells and significantly reduces tumor cell load while increasing survival time in mouse models of AML. ORY-1001 is in clinical trials for cancer treatment.
Product Specifications
Shipping Conditions
gel pack
Storage Conditions
-20°C
Shelf Life
36 months
Frequently Asked Questions
More Discoveries
Explore Other Products
Browse additional items from our catalog